pembrolizumab and berahyaluronidase alfa-pmph

What changed in the last 90 days

Every detected change for pembrolizumab and berahyaluronidase alfa-pmph, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

Same drug class

Other molecules FDA puts in Programmed Death Receptor-1 Blocking Antibody, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

• atezolizumab and hyaluronidase-tqjs· 1 maker
• nivolumab and hyaluronidase-nvhy· 1 maker
• nivolumab and relatlimab-rmbw· 1 maker
• retifanlimab-dlwr· 1 maker
• toripalimab-tpzi· 1 maker
• atezolizumab· 2 makers
• dostarlimab· 2 makers
• tislelizumab-jsgr· 2 makers
• pembrolizumab· 5 makers
• nivolumab· 6 makers

Common questions

Is Pembrolizumab and berahyaluronidase alfa-pmph in shortage right now?

No. FDA does not currently list Pembrolizumab and berahyaluronidase alfa-pmph in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.

Who makes Pembrolizumab and berahyaluronidase alfa-pmph?

1 company has marketed Pembrolizumab and berahyaluronidase alfa-pmph in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.